OPKO Health, Inc. (NASDAQ:OPK) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages

OPKO Health, Inc. (NASDAQ:OPK) has received a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $3.42.

Several analysts recently commented on the company. UBS Group set a $4.00 target price on OPKO Health in a report on Friday, October 16th. Weiss Ratings restated a “sell (d-)” rating on shares of OPKO Health in a report on Thursday, August 13th. Zacks Research upgraded shares of OPKO Health from a “hold” rating to a “strong-buy” rating in a report on Monday, September 28th. Piper Sandler restated an “overweight” rating and issued a $4.00 price target (up from $3.00) on shares of OPKO Health in a research report on Friday, October 16th. Finally, Barrington Research raised shares of OPKO Health from a “market perform” rating to an “outperform” rating and set a $2.25 price objective on the stock in a research note on Friday, October 16th.

Hedge Funds Weigh In On OPKO Health

Hedge funds have recently bought and sold shares of the company. Two Sigma Securities LLC bought a new position in shares of OPKO Health in the 2nd quarter worth about $27,000. Partners Wealth Management LLC acquired a new position in shares of OPKO Health in the 3rd quarter valued at about $43,000. Apella Capital LLC bought a new stake in shares of OPKO Health during the 1st quarter valued at about $34,000. EP Wealth Advisors LLC bought a new stake in shares of OPKO Health during the 2nd quarter valued at about $45,000. Finally, Diversify Advisory Services LLC bought a new stake in shares of OPKO Health during the 2nd quarter valued at about $37,000. Institutional investors own 64.63% of the company’s stock.

OPKO Health Price Performance

Shares of OPK opened at $1.72 on Wednesday. OPKO Health has a 1 year low of $0.98 and a 1 year high of $1.81. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.35 and a quick ratio of 2.93. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of -19.11 and a beta of 1.52. The business has a 50-day moving average of $1.57 and a 200-day moving average of $1.35.

About OPKO Health

OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Through its BioReference Laboratories business, the company provides clinical laboratory services, including routine testing, specialty diagnostics, genetic testing and oncology-related laboratory services. OPKO also develops diagnostic products, including the 4Kscore test, a blood test designed to help assess the risk of aggressive prostate cancer.

In pharmaceuticals, OPKO develops treatments for kidney disease, endocrine disorders and other conditions.